Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Clin Cancer Res ; 24(14): 3242-3246, 2018 07 15.
Article in English | MEDLINE | ID: mdl-29476018

ABSTRACT

On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a monotherapy for the treatment of adult patients with newly diagnosed CD33-positive acute myeloid leukemia (AML). Gemtuzumab ozogamicin is a CD33-targeted antibody-drug conjugate joined to calicheamicin. Approval of gemtuzumab ozogamicin combination treatment was based on a randomized trial of 271 patients with newly diagnosed AML treated with daunorubicin and cytarabine with or without 3 mg/m2 fractionated gemtuzumab ozogamicin, which resulted in an event-free survival (EFS) of 13.6 months for gemtuzumab ozogamicin + daunorubicin and cytarabine and 8.8 months for daunorubicin and cytarabine alone [HR = 0.68 (95% confidence interval (CI), 0.51-0.91)]. Hemorrhage, prolonged thrombocytopenia, and veno-occlusive disease were serious toxicities that were more common in patients treated with gemtuzumab ozogamicin + daunorubicin and cytarabine. Approval of gemtuzumab ozogamicin monotherapy was based on a randomized trial of 237 patients with newly diagnosed AML treated without curative intent. Median overall survival (OS) was 4.9 months with gemtuzumab ozogamicin versus 3.6 months on best supportive care [HR = 0.69 (95% CI, 0.53-0.90)]. Adverse events were similar on both arms. Postapproval, several studies are required including evaluation of fractionated gemtuzumab ozogamicin pharmacokinetics, safety of combination gemtuzumab ozogamicin in the pediatric population, immunogenicity, and the effects of gemtuzumab ozogamicin on platelet function. Clin Cancer Res; 24(14); 3242-6. ©2018 AACR.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Drug Approval , Gemtuzumab/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/metabolism , Sialic Acid Binding Ig-like Lectin 3/metabolism , Adult , Antineoplastic Agents, Immunological/pharmacology , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gemtuzumab/pharmacology , Humans , Leukemia, Myeloid, Acute/diagnosis , Treatment Outcome
2.
Int J Infect Dis ; 37: 152-8, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26164777

ABSTRACT

BACKGROUND: In an attempt to better understand the non-O1/O139 isolates of Vibrio cholerae, a systematic study of clinical and environmental isolates collected from various geographical locations between the years 1932 and 1998 was conducted. METHODS: Ninety-nine V. cholerae isolates collected from clinical and environmental sources from various geographical regions between 1932 and 1998 were studied by sequencing seven housekeeping genes. Genetic relatedness was defined by multiple methods that allow for the observed high levels of recombination. RESULTS: Four V. cholerae subpopulations were determined. One subpopulation contained mostly environmental isolates, a second contained the cholera toxin-positive serogroup O1/O139 isolates, and the other two subpopulations were enriched for non-O1/O139 clinical isolates that were frequently clonally related to each other. CONCLUSIONS: The data suggest that many of these non-O1/O139 clinical isolates were phylogenetically related to common ancestors, even though the isolates had been collected up to 36 years apart and from different countries or continents.


Subject(s)
Vibrio cholerae non-O1/genetics , Environmental Microbiology , Humans , Vibrio Infections/microbiology , Vibrio cholerae non-O1/classification , Vibrio cholerae non-O1/isolation & purification
3.
BMC Immunol ; 15: 51, 2014 Oct 30.
Article in English | MEDLINE | ID: mdl-25359572

ABSTRACT

BACKGROUND: The naïve antibody repertoire is initially dependent upon the number of germline V(D)J genes and the ability of recombined heavy and light chains to pair. Individual VH and VL genes are not equally represented in naïve mature B cells, suggesting that positive and negative selection also shape the antibody repertoire. Among the three member murine Vκ10 L chain family, the Vκ10C gene is under-represented in the antibody repertoire. Although it is structurally functional and accessible to both transcriptional and recombination machinery, the Vκ10C promoter is inefficient in pre-B cell lines and productive Vκ10C rearrangements are lost as development progresses from pre-B cells through mature B cells. This study examined VH/Vκ10 pairing, promoter mutations, Vκ10 transcript levels and receptor editing as possible factors that are responsible for loss of productive Vκ10C rearrangements in developing B cells. RESULTS: We demonstrate that the loss of Vκ10C expression is not due to an inability to pair with H chains, but is likely due to a combination of other factors. Levels of mRNA are low in sorted pre-B cells and undetectable in B cells. Mutation of a single base in the three prime region of the Vκ10C promoter increases Vκ10C promoter function in pre-B cell lines. Pre-B and B cells harbor disproportionate levels of receptor-edited productive Vκ10C rearrangements. CONCLUSIONS: Our findings suggest that the weak Vκ10C promoter initially limits the amount of available Vκ10C L chain for pairing with H chains, resulting in sub-threshold levels of cell surface B cell receptors, insufficient tonic signaling and subsequent receptor editing to limit the numbers of Vκ10C-expressing B cells emigrating from the bone marrow to the periphery.


Subject(s)
Antibodies/genetics , Genes, Immunoglobulin Light Chain , Animals , Base Sequence , Female , Gene Rearrangement, B-Lymphocyte, Light Chain , Immunoglobulin Heavy Chains/genetics , Male , Mice, Inbred BALB C , Molecular Sequence Data , Precursor Cells, B-Lymphoid/metabolism , Promoter Regions, Genetic/genetics , Receptors, Antigen, B-Cell/metabolism , Recombination, Genetic/genetics
4.
PLoS One ; 9(9): e106699, 2014.
Article in English | MEDLINE | ID: mdl-25268771

ABSTRACT

Monoclonal antibodies are important tools in research and since the 1990s have been an important therapeutic class targeting a wide variety of diseases. Earlier methods of mAb production relied exclusively on the lengthy process of making hybridomas. The advent of phage display technology introduced an alternative approach for mAb production. A potential concern with this approach is its complete dependence on an in vitro selection process, which may result in selection of V(H)-V(L) pairs normally eliminated during the in vivo selection process. The diversity of V(H)-V(L) pairs selected from phage display libraries relative to an endogenous response is unknown. To address these questions, we constructed a panel of hybridomas and a phage display library using the spleen of a single tetanus toxoid-immunized mouse and compared the diversity of the immune response generated using each technique. Surprisingly, the tetanus toxoid-specific antibodies produced by the hybridoma library exhibited a higher degree of V(H)-V(L) genetic diversity than their phage display-derived counterparts. Furthermore, the overlap among the V-genes from each library was very limited. Consistent with the notion that accumulation of many small DNA changes lead to increased antigen specificity and affinity, the phage clones displayed substantial micro-heterogeneity. Contrary to previous reports, we found that antigen specificity against tetanus toxoid is encoded by both V(κ) and V(H) genes. Finally, the phage-derived tetanus-specific clones had a lower binding affinity than the hybridomas, a phenomenon thought to be the result of random pairing of the V-genes.


Subject(s)
Tetanus Toxin/immunology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/biosynthesis , Antibody Affinity , Antibody Formation , Antibody Specificity , Base Sequence , Cell Surface Display Techniques , Escherichia coli , Female , Hybridomas , Immunoglobulin Fab Fragments/biosynthesis , Mice, Inbred BALB C , Molecular Sequence Data , Sequence Homology, Amino Acid , VDJ Exons
5.
Appl Environ Microbiol ; 77(7): 2247-53, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21317260

ABSTRACT

O-antigen biosynthetic (wbf) regions for Vibrio cholerae serogroups O5, O8, and O108 were isolated and sequenced. Sequences were compared to those of other published V. cholerae O-antigen regions. These wbf regions showed a high degree of heterogeneity both in gene content and in gene order. Genes identified frequently showed greater similarities to polysaccharide biosynthesis genes from species other than V. cholerae. Our results demonstrate the plasticity of O-antigen genes in V. cholerae, the diversity of the genetic pool from which they are drawn, and the likelihood that new pandemic serogroups will emerge.


Subject(s)
Biosynthetic Pathways/genetics , Genetic Variation , O Antigens/biosynthesis , Vibrio cholerae/genetics , Vibrio cholerae/metabolism , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Gene Order , Molecular Sequence Data , Sequence Analysis, DNA , Synteny
SELECTION OF CITATIONS
SEARCH DETAIL